There is no consensus as to whether terrorism should be regarded as a war crime.The Global Terrorism Database, maintained by the University of Maryland, College Park, has recorded more than 61,000 incidents of non-state terrorism, resulting in at least 140,000 deaths, between 2000 and 2014. Etymology
Etymologically, the word terror is derived from the Latin verb Tersere, which later becomes Terrere. The latter form appears in European languages as early as the 12th century; its first known use in French is the word terrible in 1160. By 1356 the word terreur is in use. Terreur is the origin of the Middle English term terrour, which later becomes the modern word "terror". Historical background
The term terroriste, meaning "terrorist", is first used in 1794 by the French philosopher François-Noël Babeuf, who denounces Maximilien Robespierres Jacobin regime as a dictatorship. In the years leading up to what became known as the Reign of Terror, the Brunswick Manifesto threatened Paris with an "exemplary, never to be forgotten vengeance: the city would be subjected to military punishment and total destruction" if the royal family was harmed, but this only increased the Revolutions will to abolish the monarchy. Some writers attitudes about French Revolution grew less favorable after the French monarchy was abolished in 1792.
Iran also approved its own version of the monoclonal antibody in January 2016, as AryoTrust, and announced its readiness to export the drug to other countries in the Middle-East and Central Asia when trade sanctions were lifted.In 2016, the investigational biosimilar MYL-1401O has shown comparable efficacy and safety to the Herceptin branded trastuzumab.Trastuzumab-dkst (Ogivri, Mylan GmbH) was approved in the United States in December 2017, to "treat patients with breast cancer or gastric or gastroesophageal junction adenocarcinoma whose tumors overexpress the HER-2 gene." Ogivri was approved for medical use in the European Union in December 2018.In November 2017, the European Commission approved Ontruzant, a biosimilar-trastuzumab from Samsung Bioepis Co., Ltd, for the treatment of early breast cancer, metastatic breast cancer and metastatic gastric cancer. Ontruzant is the first trastuzumab biosimilar to receive regulatory approval in Europe.Herzuma was approved for medical use in the European Union in February 2018. Herzuma, a trastuzumab biosimilar, was approved in the United States in December 2018. The approval was based on comparisons of extensive structural and functional product characterization, animal data, human pharmacokinetic, clinical immunogenicity, and other clinical data demonstrating that Herzuma is biosimilar to US Herceptin.